Literature DB >> 11697476

Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA.

M Singh1, G Ott, J Kazzaz, M Ugozzoli, M Briones, J Donnelly, D T O'Hagan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11697476     DOI： 10.1023/a:1012269226066

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.580


× No keyword cloud information.
  16 in total

1.  The role of CpG motifs in innate immunity.

Authors:  A M Krieg
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

2.  Cationic microparticles: A potent delivery system for DNA vaccines.

Authors:  M Singh; M Briones; G Ott; D O'Hagan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  CpG motifs as immune adjuvants.

Authors:  D M Klinman; K M Barnhart; J Conover
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

4.  Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

Authors:  J Kazzaz; J Neidleman; M Singh; G Ott; D T O'Hagan
Journal:  J Control Release       Date:  2000-07-03       Impact factor: 9.776

5.  Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.

Authors:  D Broide; J Schwarze; H Tighe; T Gifford; M D Nguyen; S Malek; J Van Uden; E Martin-Orozco; E W Gelfand; E Raz
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

6.  CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Authors:  R D Weeratna; M J McCluskie; Y Xu; H L Davis
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

7.  CpG motifs in bacterial DNA trigger direct B-cell activation.

Authors:  A M Krieg; A K Yi; S Matson; T J Waldschmidt; G A Bishop; R Teasdale; G A Koretzky; D M Klinman
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

Review 8.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.

Authors:  G Ott; G L Barchfeld; D Chernoff; R Radhakrishnan; P van Hoogevest; G Van Nest
Journal:  Pharm Biotechnol       Date:  1995

9.  Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.

Authors:  T Tokunaga; H Yamamoto; S Shimada; H Abe; T Fukuda; Y Fujisawa; Y Furutani; O Yano; T Kataoka; T Sudo
Journal:  J Natl Cancer Inst       Date:  1984-04       Impact factor: 13.506

10.  DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen.

Authors:  S Sun; H Kishimoto; J Sprent
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307
View more
  21 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

4.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

Authors:  Ashley L St John; Cheryl Y Chan; Herman F Staats; Kam W Leong; Soman N Abraham
Journal:  Nat Mater       Date:  2012-01-22       Impact factor: 43.841

5.  Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.

Authors:  Yan Yue; Wei Xu; Sidong Xiong
Journal:  DNA Cell Biol       Date:  2011-10-11       Impact factor: 3.311

Review 6.  Recent advances in oral vaccine development: yeast-derived β-glucan particles.

Authors:  Rebecca De Smet; Liesbeth Allais; Claude A Cuvelier
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

7.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 8.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

9.  Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Authors:  Ming-Hsi Huang; Su-Chen Lin; Chia-Hsin Hsiao; Hsin-Ju Chao; Hung-Ren Yang; Chien-Chun Liao; Po-Wei Chuang; Huang-Pi Wu; Chiung-Yi Huang; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen; Ai-Hsiang Chou; Alan Yung-Chih Hu; Pele Chong
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 10.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.